AAZTA-NI-PSMA-093

AAZTA-NI-PSMA-093 is a bispecific agent targeting prostate-specific membrane antigen (PSMA) with an IC50 value for PSMA of 87.48 nM. AAZTA-NI-PSMA-093 has a PSMA targeting module and an oxygen-sensitivity module (hypoxia-sensitive NI-moiety) . AAZTA-NI-PSMA-093 can utilize the PSMA targeting property as a "navigation system" to efficiently concentrate the entire molecule within prostate cancer cells, and once the cells are in an oxygen-deficient state, the molecule will irreversibly capture and remain in the oxygen-deficient cells, achieving "secondary enrichment". AAZTA-NI-PSMA-093 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu, and has high accumulation and rapid clearance characteristics in mouse models. AAZTA-NI-PSMA-093 can be used for the study of prostate cancer[1].

12352209

PSMA

Immunology/Inflammation

Cancer-programmed cell death

Cancer

O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC(COC1=CC=C(C[C@H](NC(CNC(CC[C@H](NC(CCCCC2(N(CC(O)=O)CC(O)=O)CN(CC(O)=O)CCN(CC(O)=O)C2)=O)C(NCCCN3C=CN=C3[N+]([O-])=O)=O)=O)=O)C(O)=O)C=C1)=O)CC4=CC=CC=C4)=O)=O

C63H86N14O26

1455.44

[1]Luo Y, et al. 68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer. J Med Chem. 2024 Aug 8;67 (15) :13491-13506.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11261/

Peptides

No Development Reported